Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBIT Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBIT Margin for 16 consecutive years, with 12.07% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 1234.0% to 12.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.58% through Dec 2025, up 482.0% year-over-year, with the annual reading at 12.58% for FY2025, 482.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 12.07% at Niagen Bioscience, down from 12.46% in the prior quarter.
  • The five-year high for EBIT Margin was 24.42% in Q4 2024, with the low at 51.08% in Q3 2021.
  • Average EBIT Margin over 5 years is 11.02%, with a median of 6.38% recorded in 2022.
  • The sharpest move saw EBIT Margin tumbled -2149bps in 2021, then skyrocketed 3607bps in 2023.
  • Over 5 years, EBIT Margin stood at 29.93% in 2021, then skyrocketed by 77bps to 6.88% in 2022, then surged by 88bps to 0.79% in 2023, then soared by 3180bps to 24.42% in 2024, then crashed by -51bps to 12.07% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 12.07%, 12.46%, and 10.24% for Q4 2025, Q3 2025, and Q2 2025 respectively.